Type II DNA topoisomerase inhibitors - Pipeline Insight, 2024

This “Type II DNA topoisomerase inhibitors - Pipeline Insight, 2024” report provides comprehensive insights about 30+ companies and 30+ pipeline drugs in Type II DNA topoisomerase inhibitors pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered

• Global coverage

Type II DNA topoisomerase inhibitors Understanding

Type II DNA topoisomerase inhibitors: Overview

Type II topoisomerases are ubiquitous enzymes that play an essential role in the control of replicative DNA synthesis and share structural and functional homology among different prokaryotic and eukaryotic organisms. Small molecules that target type II topoisomerase are divided into two classes: inhibitors and poisons. Due to their frequent presence in proliferating eukaryotic cells, inhibitors of type II topoisomerases have been extensively studied and used as anti-cancer medications.

Report Highlights

The companies and academics are working to assess challenges and seek opportunities that could influence Type II DNA topoisomerase inhibitors R&D. The therapies under development are focused on novel approaches for Type II DNA topoisomerase inhibitors.

Type II DNA topoisomerase inhibitors Emerging Drugs Chapters

This segment of the Type II DNA topoisomerase inhibitors report encloses its detailed analysis of various drugs in different stages of clinical development, including phase III, II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Type II DNA topoisomerase inhibitors Emerging Drugs

TRP-1001: Tryp Therapeutics Tryp is developing TRP-1001, an oral formulation of razoxane for the treatment of soft tissue sarcoma. Currently, it is in Phase II stage of development to treat soft tissue sarcoma.

Mitoxantrone liposomal: CSPC ZhongQi Pharmaceutical TechnologyA liposomal formulation of mitoxantrone is being developed by CSPC ZhongQi Pharmaceutical Technology, for the treatment of solid tumours and lymphoma. Currently, it is in preregistration stage of development to treat Peripheral T-cell lymphoma.

Type II DNA topoisomerase inhibitors: Therapeutic Assessment

This segment of the report provides insights about the different Type II DNA topoisomerase inhibitors drugs segregated based on following parameters that define the scope of the report, such as:

Major Players working on Type II DNA topoisomerase inhibitors

There are approx. 30+ key companies which are developing the Type II DNA topoisomerase inhibitors. The companies which have their Type II DNA topoisomerase inhibitors drug candidates in the most advanced stage, i.e. Preregistration include, CSPC ZhongQi Pharmaceutical Technology.

Phases

This report covers around 30+ products under different phases of clinical development like

• Late-stage products (Phase III and
• Mid-stage products (Phase II and
• Early-stage products (Phase I/II and Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates

Route of Administration

Type II DNA topoisomerase inhibitors pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

• Infusion
• Intradermal
• Intramuscular
• Intranasal
• Intravaginal
• Oral
• Parenteral
• Subcutaneous
• Topical

Molecule Type

Products have been categorized under various Molecule types such as

• Vaccines
• Monoclonal Antibody
• Peptides
• Polymer
• Small molecule

Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Type II DNA topoisomerase inhibitors: Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase III, II, I, preclinical and discovery stage. It also analyses Type II DNA topoisomerase inhibitors therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Type II DNA topoisomerase inhibitors drugs.

Type II DNA topoisomerase inhibitors Report Insights

• Type II DNA topoisomerase inhibitors Pipeline Analysis
• Therapeutic Assessment
• Unmet Needs
• Impact of Drugs

Type II DNA topoisomerase inhibitors Report Assessment

• Pipeline Product Profiles
• Therapeutic Assessment
• Pipeline Assessment
• Inactive drugs assessment
• Unmet Needs

Key Questions

Current Scenario and Emerging Therapies:

• How many companies are developing Type II DNA topoisomerase inhibitors drugs?
• How many Type II DNA topoisomerase inhibitors drugs are developed by each company?
• How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Type II DNA topoisomerase inhibitors?
• What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the Type II DNA topoisomerase inhibitors therapeutics?
• What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
• What are the clinical studies going on for Type II DNA topoisomerase inhibitors and their status?
• What are the key designations that have been granted to the emerging drugs?

Key Players

• Tryp Therapeutics
• CSPC ZhongQi Pharmaceutical Technology
• Oasmia Pharmaceutical
• Aradigm
• Teclison
• Denovo Biopharma
• NanoCarrier
• EnGeneIC
• Avacta
• Shasqi
• SkinJect
• Lantern Pharma
• Double Bond Pharmaceutical
• POP Biotechnologies
• LIDDS
• TenNor Therapeutics
• Exelixis
• EnGeneIC

Key Products

• TRP-1001
• Mitoxantrone liposomal
• Doxophos
• Apulmiq
• Tirazone
• DB 106
• NC 6003
• VEDVDox
• AVA 6000
• SQ 3370
• Doxorubicin-containing MNA
• LP 184
• SA 033
• Doxorubicin/Porphyrin phospholipid nanoparticles
• NZ DOX
• PNU-159682 based antibody drug conjugate
• E-EDV-D682

This product will be delivered within 2-4 business days.